vs
FTC Solar, Inc.（FTCI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
FTC Solar, Inc.的季度营收约是REGENXBIO Inc.的1.1倍（$32.9M vs $30.3M），FTC Solar, Inc.净利率更高（-110.7% vs -221.3%，领先110.6%），FTC Solar, Inc.同比增速更快（148.9% vs 43.0%），FTC Solar, Inc.自由现金流更多（$-8.4M vs $-52.8M），过去两年FTC Solar, Inc.的营收复合增速更高（61.6% vs 39.4%）
FTC Solar是全球领先的太阳能跟踪系统供应商，主要研发、生产和销售太阳能跟踪支架、配套组件及相关软件解决方案，服务于公用事业级、工商业光伏项目领域，业务覆盖全球主要市场，助力客户提升光伏发电效率、降低项目成本。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FTCI vs RGNX — 直观对比
营收规模更大
FTCI
是对方的1.1倍
$30.3M
营收增速更快
FTCI
高出105.9%
43.0%
净利率更高
FTCI
高出110.6%
-221.3%
自由现金流更多
FTCI
多$44.4M
$-52.8M
两年增速更快
FTCI
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $32.9M | $30.3M |
| 净利润 | $-36.4M | $-67.1M |
| 毛利率 | 14.9% | — |
| 营业利润率 | -17.2% | -190.0% |
| 净利率 | -110.7% | -221.3% |
| 营收同比 | 148.9% | 43.0% |
| 净利润同比 | -197.4% | -31.2% |
| 每股收益（稀释后） | $-2.31 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTCIRGNX
| Q4 25 | $32.9M | $30.3M | ||
| Q3 25 | $26.0M | $29.7M | ||
| Q2 25 | $20.0M | $21.4M | ||
| Q1 25 | $20.8M | $89.0M | ||
| Q4 24 | $13.2M | $21.2M | ||
| Q3 24 | $10.1M | $24.2M | ||
| Q2 24 | $11.4M | $22.3M | ||
| Q1 24 | $12.6M | $15.6M |
净利润FTCIRGNX
| Q4 25 | $-36.4M | $-67.1M | ||
| Q3 25 | $-23.9M | $-61.9M | ||
| Q2 25 | $-15.4M | $-70.9M | ||
| Q1 25 | $-3.8M | $6.1M | ||
| Q4 24 | $-12.2M | $-51.2M | ||
| Q3 24 | $-15.4M | $-59.6M | ||
| Q2 24 | $-12.2M | $-53.0M | ||
| Q1 24 | $-8.8M | $-63.3M |
毛利率FTCIRGNX
| Q4 25 | 14.9% | — | ||
| Q3 25 | 6.1% | — | ||
| Q2 25 | -19.6% | — | ||
| Q1 25 | -16.6% | — | ||
| Q4 24 | -29.1% | 70.2% | ||
| Q3 24 | -42.5% | 48.8% | ||
| Q2 24 | -20.5% | 52.5% | ||
| Q1 24 | -16.7% | 72.6% |
营业利润率FTCIRGNX
| Q4 25 | -17.2% | -190.0% | ||
| Q3 25 | -29.6% | -176.3% | ||
| Q2 25 | -57.5% | -296.3% | ||
| Q1 25 | -50.8% | 13.6% | ||
| Q4 24 | -101.7% | -242.1% | ||
| Q3 24 | -147.8% | -256.6% | ||
| Q2 24 | -104.3% | -251.3% | ||
| Q1 24 | -99.3% | -408.8% |
净利率FTCIRGNX
| Q4 25 | -110.7% | -221.3% | ||
| Q3 25 | -92.0% | -208.3% | ||
| Q2 25 | -77.2% | -331.8% | ||
| Q1 25 | -18.4% | 6.8% | ||
| Q4 24 | -92.7% | -241.3% | ||
| Q3 24 | -151.5% | -246.3% | ||
| Q2 24 | -107.1% | -237.7% | ||
| Q1 24 | -69.7% | -405.4% |
每股收益（稀释后）FTCIRGNX
| Q4 25 | $-2.31 | $-1.30 | ||
| Q3 25 | $-1.61 | $-1.20 | ||
| Q2 25 | $-1.18 | $-1.38 | ||
| Q1 25 | $-0.58 | $0.12 | ||
| Q4 24 | $-0.95 | $-0.99 | ||
| Q3 24 | $-1.21 | $-1.17 | ||
| Q2 24 | $-0.97 | $-1.05 | ||
| Q1 24 | $-0.70 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $21.1M | $230.1M |
| 总债务越低越好 | $9.9M | — |
| 股东权益账面价值 | $-43.0M | $102.7M |
| 总资产 | $111.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FTCIRGNX
| Q4 25 | $21.1M | $230.1M | ||
| Q3 25 | $24.4M | $274.2M | ||
| Q2 25 | $3.5M | $323.3M | ||
| Q1 25 | $5.9M | $267.9M | ||
| Q4 24 | $11.2M | $234.7M | ||
| Q3 24 | $8.3M | $255.5M | ||
| Q2 24 | $10.8M | $290.4M | ||
| Q1 24 | $14.0M | $338.7M |
总债务FTCIRGNX
| Q4 25 | $9.9M | — | ||
| Q3 25 | $16.6M | — | ||
| Q2 25 | $10.9M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | $9.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FTCIRGNX
| Q4 25 | $-43.0M | $102.7M | ||
| Q3 25 | $-13.7M | $161.5M | ||
| Q2 25 | $9.0M | $213.7M | ||
| Q1 25 | $15.5M | $274.2M | ||
| Q4 24 | $19.0M | $259.7M | ||
| Q3 24 | $30.4M | $301.4M | ||
| Q2 24 | $44.2M | $348.3M | ||
| Q1 24 | $55.2M | $390.7M |
总资产FTCIRGNX
| Q4 25 | $111.8M | $453.0M | ||
| Q3 25 | $111.5M | $525.2M | ||
| Q2 25 | $83.0M | $581.0M | ||
| Q1 25 | $84.1M | $490.9M | ||
| Q4 24 | $89.9M | $466.0M | ||
| Q3 24 | $91.7M | $519.1M | ||
| Q2 24 | $100.3M | $569.4M | ||
| Q1 24 | $115.0M | $629.2M |
负债/权益比FTCIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.20× | — | ||
| Q1 25 | 0.65× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-8.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | -25.7% | -174.0% |
| 资本支出强度资本支出/营收 | 1.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-34.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FTCIRGNX
| Q4 25 | $-8.0M | $-52.3M | ||
| Q3 25 | $-14.6M | $-56.0M | ||
| Q2 25 | $-2.3M | $-49.3M | ||
| Q1 25 | $-8.5M | $33.6M | ||
| Q4 24 | $-16.7M | $-31.6M | ||
| Q3 24 | $-2.4M | $-40.5M | ||
| Q2 24 | $-3.8M | $-45.5M | ||
| Q1 24 | $-11.9M | $-55.5M |
自由现金流FTCIRGNX
| Q4 25 | $-8.4M | $-52.8M | ||
| Q3 25 | $-15.1M | $-56.5M | ||
| Q2 25 | $-2.5M | $-49.7M | ||
| Q1 25 | $-8.6M | $32.6M | ||
| Q4 24 | $-17.0M | $-32.7M | ||
| Q3 24 | $-2.6M | $-40.9M | ||
| Q2 24 | $-4.5M | $-46.0M | ||
| Q1 24 | $-12.3M | $-56.0M |
自由现金流率FTCIRGNX
| Q4 25 | -25.7% | -174.0% | ||
| Q3 25 | -57.9% | -189.9% | ||
| Q2 25 | -12.4% | -232.8% | ||
| Q1 25 | -41.2% | 36.6% | ||
| Q4 24 | -128.6% | -154.2% | ||
| Q3 24 | -25.6% | -168.9% | ||
| Q2 24 | -39.2% | -206.2% | ||
| Q1 24 | -97.6% | -358.5% |
资本支出强度FTCIRGNX
| Q4 25 | 1.3% | 1.7% | ||
| Q3 25 | 1.7% | 1.7% | ||
| Q2 25 | 0.9% | 1.8% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 2.2% | 5.1% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 6.1% | 2.1% | ||
| Q1 24 | 3.4% | 3.6% |
现金转化率FTCIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTCI
| Products | $26.2M | 80% |
| Services | $6.7M | 20% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
